It’s only fair to share… Envudeucitinib CAS 2417135-66-9 MF C22H18[2]H6N6O3 MW426.5 g/mol N-[4-{2-methoxy-3-[1-(2H3)methyl-1H-1,2,4-triazol-3-yl]anilino}-5-(3,3,3-2H3)propanoylpyridin-2-yl] cyclopropanecarboxamide N-(4-(2-methoxy-3-(1-(trideuteriomethyl)-1,2,4-triazol-3-yl)anilino)-5-(3,3,3-trideuteriopropanoyl)pyridin-2-yl)cyclopropanecarboxamide N-[4-[2-methoxy-3-[1-(trideuteriomethyl)-1,2,4-triazol-3-yl]anilino]-5-(3,3,3-trideuteriopropanoyl)pyridin-2-yl]cyclopropanecarboxamideJanus kinase inhibitor, anti-inflammatory, Fronthera U.S. Pharmaceuticals, psoriasis, FTP 637 Envudeucitinib is an investigational new drug that is being evaluated for the treatment of psoriasis. It is a selective tyrosine kinase 2 (TYK2) inhibitor developed by Fronthera U.S. Pharmaceuticals LLC and now owned by Alumis, Inc. for …